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Abstract
Background: Pulmonary tuberculosis (PTB) is an increasing global health problem that continues to cause significant morbidity and 
mortality. The impact of PTB has been measured in terms morbidity and mortality and little attention has been paid to continuing 
respiratory disability in those who were cured. Pulmonary hypertension (PHT) is a serious respiratory disability that results from 
  structural lung damage and chronic hypoxia. This study was conducted to investigate the presence of PHT in a cohort of treated PTB 
patients who presented with shortness of breath.
Methods: This is a cross-sectional study that included 14 consecutive patients who were cured of PTB and presented with shortness of 
breath. Demographic and clinical data were recorded for all patients. PHT was diagnosed using Doppler echocardiography.
Results: Fourteen patients who were treated for PTB and were found to have PHT were studied. All patients were sputum smear negative 
at the time of the study. The mean age (SD) was 43.1 (13.6) and half of the patients were males. The mean number of years since PTB 
was diagnosed (SD) was 9.4 (10.9). All patients had abnormal chest x-rays. The commonest radiological abnormality was fibrocavita-
tion which occurred in 50% of patients. Estimated pulmonary artery systolic pressure (PASP) of 51 to 80 mm/Hg was found in 9 patients 
(64.3%) whereas PASP of 40 to 50 mm/Hg was found in 4 patients (28.6%) and one patient had PASP more than 80 mm/Hg.
Conclusions: Different grades of PHT occurred in this cohort of treated PTB patients on average about 9 years after cure. The findings 
of this study support implementation of strategies for early detection and prevention of PTB. For those who were cured from PTB, 
longer periods of disability should be implemented in assessment of disease burden.
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Introduction
PTB continues to be a major global health   problem 
causing significant morbidity and mortality in spite 
of modern and effective chemotherapy.1 Many   factors 
contribute to the increase in PTB worldwide including 
homelessness, poverty, immigration, lack of   public 
health infrastructure, limited access to medical care, 
in addition to the HIV epidemic, and these factors 
are likely to continue in the foreseeable future.2 The 
impact of PTB has traditionally been measured in 
terms of morbidity and mortality. Treatment success 
in PTB has been defined in terms of microbiological 
cure rates and little attention has been paid to the 
impact of PTB as a cause of disability in those who 
survived the disease.1 Given the high incidence of 
PTB and the high success rate of modern therapy there 
is an unknown but substantial number of patients who 
survived PTB worldwide.1
Studies that assessed the impact of treated PTB as 
a cause of disability have focused on impairment of 
lung function.3–5 These studies have shown significant 
residual lung function impairment in more than 50% 
of  treated  PTB  patients  and  both  obstructive  and 
restrictive ventilatory defects have been described.3–5 
It is known that persisting physiological impairment 
leads  to  gas  exchange  abnormalities  and  develop-
ment of pulmonary hypertension which is a cause of 
severe disability and reduced longevity.6–8 However, 
few  studies  described  pulmonary  hypertension  in 
treated PTB patients and most of the available infor-
mation is from the pre-chemotherapy era.9 We there-
fore conducted this study to investigate the presence 
of  pulmonary  hypertension  in  a  cohort  of  patients 
who survived PTB as a result of treatment and pre-
sented with shortness of breath. This is a pilot study 
of a project that aims to follow up survivors of PTB 
with a view to assess prevalence and progression of 
physiological impairment, radiological abnormalities 
and PHT in these patients.
Materials and Methods
This  is  a  descriptive  cross-sectional  study  that 
included 14 consecutive patients with treated PTB 
who presented with shortness of breath. Patients were 
recruited from the respiratory department of a tertiary 
referral hospital: Elshaab Hospital, Khartoum, Sudan. 
Ethical approval for the study was obtained from the 
ethical committee of the hospital and all patients gave 
informed consent to take part in the study. Patients 
with  a  history  of  treated    pulmonary  tuberculosis 
  diagnosed on basis of positive sputum smear test who 
presented with shortness of breath were investigated 
for the presence of PHT and if found to have PHT 
were  included  in  the  study.  All  patients  received 
  antituberculous therapy at the time of diagnosis as in 
the protocol of Sudan National Tuberculosis Program. 
The  daily  regimen  is  composed  of  intramuscular 
streptomycin for two months, oral pyrazinamide for 
two months, oral rifampicin for six months and oral 
isoniazid for six months. All patients had chest radio-
graphs and these were reviewed. Data on age, sex, 
history  of  tuberculosis  including  time  and  method 
of  diagnosis  and  treatment  received  and  its  dura-
tion were collected using a structured   questionnaire. 
All  patients  underwent  a  full  clinical  examina-
tion and physical signs were recorded using a spe-
cially designed clinical sheet. Patients with cardiac 
valvular lesions and those who were HIV positive 
were  excluded  from  the  study.  Patients  underwent 
Doppler  echocardiography  using  a  GE  Vivid  3Pro 
and  Esaote  MyLab™50  XVision  echocardiography 
machine.    Tricuspid  regurgitation  was  identified  in 
the best possible view for proper continuous wave 
alignment. Right atrium/right ventricle pressure gra-
dient  (RA/RVPG)  was  calculated  using  simplified 
Bernoulli equation.10 PASP was identified using the 
equation PASP = RA/RV PG + right atrial pressure 
mm/Hg estimated using IVC collapsibility index.10 
PHT was considered as PASP $ 40 mm/Hg.10
Results
A total of 30 patients who were treated for PTB and 
presented  with  shortness  of  breath  were  screened 
for the presence of PHT. Fourteen of these patients 
were found to have PHT and were included in the 
study. Table 1 shows the demographic and clinical 
characteristics of the 14 patients studied. There were 
equal numbers of men and women with a mean age 
of 43.7 years. All patients were initially diagnosed on 
basis of a positive sputum smear test, but none was 
sputum  smear  positive  at  the  time  of  inclusion  in 
the study. The mean number of years since PTB was 
diagnosed was 9.4 years. Eight patients completed 
treatment and the rest defaulted. Seventy nine   percent Pulmonary hypertension in patients with treated pulmonary tuberculosis
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of  the  patients  were  non  smokers.  Table  2  shows 
the radiological abnormalities at the time the study 
was  conducted.  All  patients  had  abnormal  chest 
radiographs. Fifty percent of the patients had residual 
fibrocavitatory  changes  and  one  patient  had  a 
fibrothorax. Table 3 shows the echocardiographically 
estimated pulmonary artery systolic pressure of the 
14 patients. Most of the patients had moderately severe 
PHT (PASP 51–80 mm/Hg) whereas only one patient 
had severe PHT (PASP more than 80 mm/Hg).
Discussion
This study documents the presence of PHT in a cohort 
of symptomatic patients who were treated from PTB 
in  a  country  with  high  tuberculosis    burden.2  Our 
study was designed to exclude other possible causes 
of PHT in this cohort of patients in that we excluded 
all patients with cardiac valvular lesions and those 
who were HIV positive.11 The percentage of   smokers 
among the study population was low at 21% making 
chronic obstructive pulmonary disease as a   possible 
cause  of  PHT  very  unlikely.6–8  Furthermore,  all 
patients we studied were sputum smear positive at the 
time when they were first diagnosed and had residual 
radiological abnormalities that are known to result 
from PTB thus excluding other forms of interstitial 
lung disease as a possible cause of PHT.
Previous studies that assessed the presence of PHT in 
PTB patients were mostly from the pre-chemotherapy 
era and PHT and cor   pulmonale were diagnosed by 
electrocardiography or at postmortem.9,12–14 Our study 
is different in that all our patients received modern 
anti-tuberculous   chemotherapy and were microbio-
logically  cured.  We  utilized  Doppler  echocardiog-
raphy  to  diagnose    pulmonary  hypertension  in  our 
patients. While Doppler echocardiography estimates 
PASP, it is by far the best method for non invasive 
diagnosis of PHT and we considered it to be accept-
able for this report.15,16 Values of pulmonary artery 
systolic pressure obtained with measurement of the 
maximum  velocity  of  tricuspid  valve  regurgitation 
using  continuous  wave  Doppler  echocardiography 
correlate  strongly  with  those  found  on  right  heart 
catheterization.17
The mechanism of development of PHT in treated 
PTB patients is thought to result from residual pul-
monary  structural  damage  and  pulmonary  function 
abnormalities leading to gas exchange abnormalities 
and chronic hypoxia.9,18 It has also been suggested that 
repeated secondary respiratory tract infections, caused 
by residual chest x-ray abnormalities, play an impor-
tant role in the pathogenesis of PHT in treated PTB 
patients.9,18 All our patients had abnormal chest radio-
graphs that were caused by PTB, but we did not mea-
sure lung function in our study population. However, 
Table  1.  Demographic  and  clinical  characteristics  of 
the 14 patients with treated pulmonary tuberculosis and 
  pulmonary hypertension.
characteristic number 
(percentage)
Age in years mean (SD) 43.1 (13.6)
Gender
  Males 7 (50%)
  Females 7 (50%)
Sputum smear test
  Positive when first diagnosed 14 (100%)
  Positive at time of inclusion in study 0 (0%)
Years since TB was first diagnosed  
mean (SD)
9.4 (10.9)
Completed Tuberculosis therapy
  Yes 8 (57%)
  Defaulted 6 (43%)
Smoking
  Current smokers 1 (7%)
  Previous smokers 2 (14%)
  non smokers 11 (79%)
Table 2. Radiological abnormalities among the 14 patients 
with  treated  pulmonary  tuberculosis  and  pulmonary 
hypertension.
chest-X-ray abnormality number 
(percentage)
Fibrocavitatory 7 (50%)
Fibrosis 5 (36%)
Bullae and fibrosis 1 (7%)
Fibrothorax 1 (7%)
Table  3.  estimated  pulmonary  artery  systolic  pressure 
among the 14 patients with treated pulmonary tuberculosis 
and pulmonary hypertension.
estimated pulmonary artery 
systolic pressure
number 
(percentage)
40–50 mm/hg 4 (28.6%)
51–80 mm/hg 9 (64.3%)
More than 80 mm/hg 1 (7.1%)Ahmed et al
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all of our patients presented with shortness of breath 
and it has been shown that symptoms of pulmonary 
function impairment generally do not occur in patients 
with chronic lung disease until the forced expiratory 
volume in the first second has fallen to 50% of that 
predicted;19 therefore, it is likely that the patients we 
studied had significant lung function impairment.
The occurrence of PHT in the course of chronic 
  pulmonary  disease  is  associated  with  accelerated 
  morbidity  and  increased  mortality.6–8 A  remarkable 
finding in this study is the young age of the patients 
diagnosed  with  PHT—mean  age  43  years.  These 
patients are much younger when compared with patients 
who have PHT in association with chronic obstructive 
pulmonary disease whose mean age was 66 years.20 
Clearly,  these  patients  developed  a  serious  respira-
tory disability at a relatively young age as a result of 
a disease which they contracted on average more than 
9 years previously and from which they were cured.
This  study  was  not  designed  to  measure  the 
prevalence of PHT in treated PTB patients; rather, it 
is a case series that documents the presence of a seri-
ous respiratory morbidity in a cohort of symptomatic 
patients after successful treatment of PTB. Studies of 
the prevalence of residual lung function abnormali-
ties in treated PTB patients have shown persistent 
pulmonary function impairment in up to 65% of these 
patients.3–5,21  Similarly,  residual  radiological  abnor-
malities  have  been  documented  in  86%  of  treated 
PTB patients.21 However, the prevalence of PHT in 
patients with residual lung function and radiologi-
cal abnormalities has not been documented in these 
studies.3–5,21  Nevertheless,  persistent  lung  function 
impairment and  residual  radiological  abnormalities 
are thought to cause PHT in patients with PTB.9,18 
Also,  the  effect  of  physiological  impairment  lead-
ing to chronic hypoxia and structural lung damage 
as causes of PHT are well documented in chronic 
lung disease.6–8 Given the global scale of PTB and 
the  increasing  number  of  patients  who  have  sur-
vived the disease because of effective therapy, we 
can  postulate  that  the  problem  of  PHT  in  treated 
PTB patients is likely to be substantial.1,2 However,   
a specially designed study to document prevalence of 
PHT in treated PTB is needed.
PHT  of  variable  degrees  occurs  in  patients 
with treated PTB. PHT as a measure of pulmonary 
impairment  contributes  important  burdens  of  PTB 
in microbiologically cured patients that may cause 
excess mortality. Current assessment of PTB burden 
assumes  that  tuberculosis  causes  disability  before 
and then immediately after diagnosis and treatment.22 
Given  the  results  of  this  study,  such  an  approach 
clearly underestimates this burden and should take into 
account longer period of disability in cured patients. 
The findings of this study support early case detection 
and treatment of latent PTB and employment of other 
preventative strategies.
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